Health and Healthcare
Why Clovis Oncology Faces Some Difficulty With Its Midstage Cancer Study
Published:
Last Updated:
Clovis Oncology Inc. (NASDAQ: CLVS) shares dropped on Friday after the company announced initial data from its Phase 2 TRITON2 clinical trial of Rubraca at the ESMO 2018 Congress of the European Society for Medical Oncology.
According to the study, the data show a 44% confirmed objective response rate by investigator assessment. The median duration of response in these patients has not yet been reached. Additionally, a 51% confirmed prostate specific antigen (PSA) response rate was observed in 45 PSA response-evaluable patients with a BRCA1/2 alteration.
The TRITON2 results were the basis for Breakthrough Therapy designation for Rubraca, which was granted on October 2, 2018, by the U.S. Food and Drug Administration (FDA).
While most of these results were positive, there was a downside. The most common treatment-emergent adverse events of any in all patients regardless of causality included asthenia/fatigue (44.7), nausea (42.4%), anemia/decreased hemoglobin (22.4%) and constipation (28.2%). Five patients (5.9%) discontinued therapy due to a non-progression treatment-emergent adverse event. One patient died due to disease progression.
Dr. Wassim Abida, medical oncologist, Memorial Sloan Kettering Cancer Center, and principal investigator for the TRITON2 study, commented:
Rubraca has previously demonstrated antitumor activity in its approved indications for women with advanced ovarian cancer. These new data show that Rubraca may also offer a new approach for the treatment of mCRPC associated with BRCA1 and BRCA2 alterations, with the potential to achieve a clinical response in patients with few remaining therapy options.
Shares of Clovis were last seen down about 4% at $28.86 Friday morning, with a consensus analyst price target of $62.40 and a 52-week trading range of $26.21 to $79.60.
24/7 Wall St.Travel Cards Are Getting Too Good To Ignore (sponsored)
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.